News Agency
Men's Weekly

Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

  • Written by PR Newswire

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independently developed and produced by Belief BioMed.

BBM-H803...

Read more: Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial...

Gender-Inclusive Lash Treatments: Breaking Beauty Norms

Beauty is no longer defined by traditional gender standards, and the lash industry is evolving to reflect that.  In 2026, more clients of all genders are seeking lash lifts, tints, and extensions that enhance their natural features while respecting individual style... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion